Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

Neuroendocrine Tumours Clinical Trial

Official title:
Phase II, Open, Single Group, Multicentre Study to Evaluate the Efficacy and Safety of Lanreotide Autogel Administered Every 4 Weeks by Deep Subcutaneous Injection in the Tumour's Growth Stabilization of Patients With Progressive Neuroendocrine Tumours Who Are Not Eligible to be Treated With Either Surgery or Chemotherapy

Status Completed

Clinical Trial Summary

To evaluate, in patients with progressive neuroendocrine tumours who are not eligible to be treated with either surgery or chemotherapy at the moment of study inclusion, the efficacy of lanreotide Autogel in tumour growth stabilization.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00326469
Study type	Interventional
Source	Ipsen
Contact
Status	Completed
Phase	Phase 2
Start date	May 2006
Completion date	November 2009

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00323076` - [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours	Phase 1/Phase 2
Completed	`NCT02075606` - Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients	Phase 4
Terminated	`NCT02788578` - A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours
Completed	`NCT01840449` - Somatuline Predictive Factors in Acromegaly and NET
Completed	`NCT02698410` - Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.	Phase 2
Active, not recruiting	`NCT02923934` - A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers	Phase 2
Completed	`NCT01673906` - 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours	Phase 2
Active, not recruiting	`NCT04579679` - Open-Label Surufatinib in European Patients With NET	Phase 2